Fundraising Fox
Rubius Therapeutics
Cambridge, US · Founded 2013 · Delaware corporation · 18 employees on LinkedIn · 4 known investors
Find your way into Rubius Therapeutics
Sign up to see every warm intro you have to Rubius Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rubius Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JP
Joanne ProtanoExecutive
DE
David EpsteinNamed on SEC filing
HF
Harvey F. LodishNamed on SEC filing
MR
Michael RosenblattNamed on SEC filing
RP
RS
Board
NB
PB
Peter Barton HuttBoard director
Investors · 4
Flagship PioneeringreportedCambridge · $500K – $10Mvia Noubar Afeyan · board
How we know: board seat on SEC Form D · funding news · fiercebiotech.com · Not right? Tell us
Flagship VenturesreportedCambridge
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
Flagship VentureLabs
Reported raises · per SEC filings
Form D private placements$216.2M disclosed across 2 rounds · 2017–2018
▶$101.2MraisedMar 2018 · 27 investors · BiotechnologyRule 506(b)
▶$101.2MraisedMar 2018 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher L. CarpenterExecutive Officer
- Torben Straight NissenExecutive Officer, Director
- Robert S. LangerDirector
- Noubar B. AfeyanDirector
- Francis CussDirector
- Catherine SohnDirector
- Michael RosenblattDirector
- Roger PomerantzDirector
- Joanne ProtanoExecutive Officer
- David EpsteinDirector
- Andrew OhExecutive Officer
- Offering amount
- $101.2M
- Amount sold
- $101.2M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$115MraisedJun 2017 · 16 investors · BiotechnologyRule 506(b)
▶$115MraisedJun 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter Barton HuttDirector
- David EpsteinDirector
- Harvey F. LodishDirector
- Michael RosenblattDirector
- Roger PomerantzDirector
- Robert S. LangerDirector
- Noubar B. AfeyanDirector
- Torben Straight NissenExecutive Officer, Director
- Joanne ProtanoExecutive Officer
- Offering amount
- $120M
- Amount sold
- $115M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Rubius Therapeutics mafia →6 people who came through Rubius Therapeutics went on to found or lead other companies.
Noubar AfeyanDirectorFounded ProFound Therapeutics +15Avak KahvejianFounding President & CEOFounded ProFound Therapeutics +5Robert LangerDirectorFounded Lyndra +2ROGER POMERANTZDirectorFounded Seres TherapeuticsKris ElverumSVP of Business Development and StrategyFounded ロゴマーク：AIRNAPablo J. CagnoniPresident and Chief Executive OfficerFounded Tizona Therapeutics, Inc.
Frequently asked questions
- Who are Rubius Therapeutics's investors?
- Rubius Therapeutics's investors include Flagship Pioneering, Flagship Ventures, Kendall Capital Partners.
- How much funding has Rubius Therapeutics raised?
- Rubius Therapeutics has disclosed $216.2M raised across 2 rounds.
- Where is Rubius Therapeutics headquartered?
- Rubius Therapeutics is headquartered in Cambridge, US.